<DOC>
	<DOC>NCT01860326</DOC>
	<brief_summary>This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of single oral doses of Alisporivir in subjects with mild and moderate hepatic impairment compared to matched healthy subjects with normal liver function.</brief_summary>
	<brief_title>Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Inclusion criteria: Male or female, 18 to 70 years of age, in good health Stable ChildTurcottePugh score of at least 5 Body weight of at least 50 kg and a BMI of 18.0 to 36.0 kg/m2 Exclusion criteria: Use of other investigational drugs Women of childbearing potential Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>hepatic impairment</keyword>
	<keyword>mild and moderate hepatic impairment</keyword>
	<keyword>Alisporivir</keyword>
</DOC>